Compare AbbVie Inc (ABBV) vs Duke Energy Corp (DUK) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Duke Energy (DUK) trades at $128.22, down 1.06% on the day, with a bullish technical signal supported by moving averages. The company shows steady revenue growth, reaching $32.24B in 2025, and has beaten earnings estimates for the last three quarters. A $1.07 dividend is scheduled for June 2026. Analyst consensus is a Buy with a $137.67 price target, though the stock faces headwinds from high debt levels and regulatory pressures.

DUK presents a stable investment with consistent earnings and a solid dividend, but investors should weigh the upside from infrastructure investments against rising debt and regulatory risks. The stock's current valuation is reasonable, with potential for moderate growth if execution on its $103B capital plan remains on track.